Gyroscope Therapeutics recently commenced phase 1/2 clinical trials on a retinal gene therapy for dry age-related macular degeneration.
Gyroscope Therapeutics, a UK-based retinal gene therapy developer partly based on University of Cambridge research, has received an undisclosed sum from Cambridge Innovation Capital, the university’s affiliate patient capital fund.
Gyroscope develops retinal gene therapies for dry age-related macular degeneration (AMD) that target genetic factors and inflammations associated with the disease.
In dry AMD, small yellowish retinal deposits form beneath the macula and cause macular cells to decay, leading to a sharp deterioration in the patient’s vision over time.
Gyroscope’s most advanced candidate, GT0005, is currently undergoing phase 1/2 clinical trials as a one-time dry AMD treatment for patients with particular genetic attributes. It aims to restore the equilibrium of an immune system mechanism known to be overactive in the disease.
Administering the therapy involves carrying out surgery to detach the patient’s retina so a virus-bearing solution containing modified DNA can be injected to correct the targeted…
